Melittin-MIL-2 fusion protein as a candidate for cancer immunotherapy

Abstract

This study provides the evidence that the melittin-MIL-2 can produce stronger immune stimulation and antitumor effects, and the fusion protein is a potent candidate for cancer immunotherapy.